To assess the contribution of IL-6 signaling inhibition on tumor progression and survival time in vivo, we crossed IL-6-/- mice with mutant KrasG12D mice because IL-6 is a downstream effector of oncogenic Ras to promote tumorigenesis[4]. Here, IL6 is linked to neoplasm.